Recent news on Interferon Beta-1B

Early Interferon Beta-1B Use in Multiple Sclerosis Patients Slows ...  -  May 2, 2007
DG NewsThese patients were treated with subcutaneous interferon beta-1b 250 mcg or placebo every other day until either a diagnosis of clinically definite MS was

AAN: Early MS Treatment with Interferon Beta-1b Delays Progression  -  May 2, 2007
MedPage Today,BOSTON, May 2 -- The risk of multiple sclerosis (MS) progression can be significantly reduced by starting patients on interferon beta-1b (Betaseron) before

Early Interferon Beta-1B (BetaseronR) In Multiple Sclerosis ...  -  May 1, 2007
Medical News Today,Prompt initiation of interferon beta-1b (BetaseronR) at the onset of suspected multiple sclerosis (MS) translates into less progression to chronic

Studies Presented at Neurology Conference Highlight Early Efficacy ...  -  May 3, 2007
PR Newswire (press release),About Betaseron Betaseron (Interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical

First Of Its Kind Data Show: Immediate Treatment Of Early MS ...  -  May 2, 2007
Medical News Today (press release),Bayer HealthCare Pharmaceuticals announced today new data, which show that immediate initiation(1) of Betaseron(R) (interferon beta-1b) treatment in

Studies Presented At Neurology Conference Highlight Early Efficacy ...  -  May 4, 2007
Medical News Today (press release),Bayer HealthCare Pharmaceuticals announced today the results of three clinical studies with Betaseron(R) (interferon beta-1b), presented this week at the

Immediate Treatment Of Early MS Patients With Betaferon ...  -  May 7, 2007
Medical News Today (press release),Bayer Schering Pharma AG, Germany, announced today new data, which show that immediate initiation of Betaferon® (interferon beta-1b) treatment in patients

Immediate Treatment Of Early Multiple Sclerosis Patients ...  -  May 2, 2007
eMaxHealth.com,...to receive either 250 micrograms of interferon beta-1b (Betaseron) every other day or placebo as a subcutaneous injection in a double blind fashion.

New One-Year Pharmacoeconomic Study Shows Avonex® Is Cost ...  -  Apr 18, 2007
Medical News Today (press release),...patients on interferon beta therapy were: AVONEX, $19896.15; Rebif® (Interferon beta-1a) sc, $22207.85; and Betaseron® (Interferon beta-1b), $21073.33.

Large Study Shows that Presence of Neutralizing Antibodies Did Not ...  -  Apr 6, 2007
Drug Newswire (press release),Betaseron (Interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations.

Large Study Shows that Presence of Neutralizing Antibodies Do Not ...  -  Apr 3, 2007
WebWire (press release),Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre

New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective ...  -  Apr 13, 2007
PharmaLive.com (press release),...on interferon beta therapy were: AVONEX, $19896.15; Rebif(R) (Interferon beta-1a) sc, $22207.85; and Betaseron(R) (Interferon beta-1b), $21073.33.

Nieuw farmaceutisch-economisch onderzoek toont aan dat AVONEX ...  -  Apr 13, 2007
Netherlands Corporate News (persbericht),...$22207.85; and Betaseron(R) (Interferon beta-1b), $21073.33. In addition, AVONEX patients were more likely to refill their prescriptions (avg.9.6/yr vs.

Novartis in MS therapy deal  -  Mar 28, 2007
England's Northwest,Bayer Schering Pharma will support Novartis in the regulatory filing process of a branded version of interferon beta-1b and will assume manufacturing

Interferon beta-1b for patients with multiple sclerosis  -  27 Mar 2007
SpiritIndia,Bayer Schering Pharma will support Novartis in the regulatory filing process of a Novartis-branded version of interferon beta-1b.

Risk Factors for Thyroid Disease  -  Mar 7, 2007
About - News & Issues,These include Interferon Beta-1b, Interleukin-4, immunosuppressants, antiretrovirals, monoclonal antibody (Campath-1H), bone marrow transplant, Lithium,

Bayer has high hopes that cancer drug Nexavar will be huge  -  Mar 16, 2007
Pharma Times (subscription),...leaping almost 84% to 7.48 billion euros in 2006, driven by Schering's Betaferon/Betaseron (interferon beta 1b) for multiple sclerosis (991 million

Bayer posts strong results for 2007  -  Mar 15, 2007
Pharma Times (subscription),...antihaemophilic factor), climbing 18.7%; and proforma turnover of Betaferon/Betaseron (interferon beta 1b) for multiple sclerosis, which grew 14.3%.

BioMS Medical: potential to broaden MS treatment options  -  Mar 2, 2007
Pharmaceutical Business ReviewAt present, only two of disease-modifying drugs, Betaseron (interferon beta-1b; Schering AG) and Novantrone (mitoxantrone; Serono) are indicated for SPMS.

Medical Edge: Plasma exchange used as treatment, not cure, for MS  -  Jan 27, 2007
Bryan College Station Eagle,The best known among them are interferon beta-1b (Betaseron) and interferon beta-1a (Avonex, Rebif), which are genetically engineered copies of proteins

Fines fail to curb bad advertising  -  Feb 16, 2007
The Australian,The two biggest fines resulted from complaints over one product – the drug Betaferon, a trade name for interferon beta-1b. Its maker, Schering, was ordered

Nektar Appoints Howard W. Robin President and CEO  -  Jan 8, 2007
PharmaLive.com (press release),...such as Betaseron(R) (Interferon beta-1b) for multiple sclerosis and Fludara(R) (fludarabine phosphate) for chronic lymphocytic leukemia,

Nektar Appoints Howard W. Robin President and CEO  -  Jan 8, 2007
Business Wire (press release),...such as Betaseron® (Interferon beta-1b) for multiple sclerosis and Fludara® (fludarabine phosphate) for chronic lymphocytic leukemia, generating annual

Diagnosis and Monitoring of Multiple Sclerosis: Focus on ...  -  Nov 27, 2006
Medscape (subscription)With interferon beta-1b, 6 of 45 black holes (13.3%) became permanent at 12 months, and at 9 months, 8 of 37 black holes became permanent.

Clinical Trial Design  -  Nov 27, 2006
Medscape (subscription)For example, patients in different secondary progressive trials of interferon beta-1b had very different disease progression results, although patients were

FDA Approves Betaseron(R) (Interferon beta-1b) for Use After the ...  Oct 23, 2006
AG, Germany, announced today that the US Food and Drug Administration (FDA) has expanded the indication of Betaseron(R) (interferon beta-1b) to include ... -DG News FDA Approvals: Yaz, Betaseron, and Nexium  Nov 2, 2006
...tablets, allowing its use in the treatment of symptoms of premenstrual dysphoric disorder; an expanded indication for interferon-beta-1b subcutaneous injection ... -Medscape (subscription) Treatment of Multiple Sclerosis at the First Demyelinating Event ...  Oct 12, 2006
CHICAGO, IL -- October 12, 2006 -- Patients with multiple sclerosis (MS) who start treatment with interferon beta-1b (Betaseron) at the time of their first ... -DG News FDA Approves Betaseron(R) for Use After the First Event Suggestive ...  Oct 25, 2006
SCH; NYSE: SHR), announced today that the US Food and Drug Administration (FDA) has expanded the indication of Betaseron(R) (interferon beta-1b) to include ... -Drug Newswire (press release), FDA Approves Betaseron(R) for Use After the First Event Suggestive ...  Oct 23, 2006
FSE: SCH; NYSE: SHR), announced today that the US Food and Drug Administration (FDA) has expanded the indication of Betaseron® (interferon beta-1b) to include ... -Yahoo! News (press release) Betaseron approved in the US for earliest stages of Multiple ...  Oct 23, 2006
...by the Bayer Group, announced today that the US Food and Drug Administration (FDA) has expanded the indication of Betaseron® (interferon beta-1b, brand name ... -WebWire (press release), Berlex MS drug OK'd for first-event use  Oct 23, 2006
The company said the Food and Drug Administration has OK'd the expanded use of its drug interferon beta-1b for patients with MS who have experienced a first ... -United Press International Betaseron Approved for Additional Indication  Oct 25, 2006
The FDA has approved Berlex Inc.’s Betaseron (interferon beta-1b) for the treatment of patients with multiple sclerosis (MS) who have experienced a first ... -Facts and Comparisons, Betaseron approved in the US for earliest stages of Multiple ...  Oct 24, 2006
10/25/2006 - Schering AG announced that the US Food and Drug Administration (FDA) has expanded the indication of Betaseron (interferon beta-1b, brand name of ... -Chemie.de (press release), Go-Ahead Given to Four Drugs for Cardio Conditions, Eczema, MS ...  Oct 23, 2006
Berlex’ Betaseron (interferon beta-1b) has been expanded to include patients with multiple sclerosis (MS) who have experienced a first clinical episode and ... -Genetic Engineering News (press release), TODAY ON PHARMALIVE.COM  Sep 12, 2006
Neither treatment with Avonex(R) (Interferon beta-1a IM) nor Betaseron(R) (Interferon beta-1b) was associated with significantly fewer days missed from work in ... -PharmaLive.com

Diagnosis and Monitoring of Multiple Sclerosis: Focus on ...  -  Nov 27, 2006
Medscape (subscription)With interferon beta-1b, 6 of 45 black holes (13.3%) became permanent at 12 months, and at 9 months, 8 of 37 black holes became permanent.

Clinical Trial Design  -  Nov 27, 2006
Medscape (subscription)For example, patients in different secondary progressive trials of interferon beta-1b had very different disease progression results, although patients were

Betaferon® approved in Australia for earliest stages of Multiple ...  -  Nov 24, 2006
PipelineReview.com (press release),Announced today that the Australian Therapeutic Goods Administration has expanded the indication of Betaferon® (interferon beta-1b) to include patients with

Betaferon(R) Approved in Australia for Earliest Stages of Multiple ...  -  Nov 23, 2006
Earthtimes.orgPatients with a first clinical demyelinating event suggestive of MS and typical MRI findings received either eight million units of interferon beta-1b

Australia OKs Expanded Use Of Schering's Betaferon Drug  -  Nov 23, 2006
Therapeutics Daily (subscription) (press release),...has expanded the indication of Betaferon (interferon beta-1b) to include patients with a first clinical event suggestive of multiple sclerosis, or MS.

Betaferon(R) (Interferon beta-1b) Approved in Canada for Treatment ...  Aug 3, 2006
BERLIN, GERMANY -- August 3, 2006 -- Schering AG, Germany announced today that Betaferon® (interferon beta-1b, marketed as Betaseron® in Canada by Schering's ... -DG News

Risk Of Developing Multiple Sclerosis Significantly Reduced With ...  Aug 18, 2006
Researchers have found that treatment of patients with interferon beta-1b after a first attack suggestive of multiple sclerosis (MS) cuts their risk of ... -Medical News Today

Trial Results Published in Neurology Show Risk of Developing ...  Aug 17, 2006
17 /PRNewswire/ -- Researchers have found that treatment of patients with interferon beta-1b after a first attack suggestive of multiple sclerosis (MS) cuts ... -Yahoo! News

Trial Shows Risk of Developing Multiple Sclerosis Significantly ...  Aug 17, 2006
OTTAWA, CANADA -- August 17, 2006 -- Researchers have found that treatment of patients with interferon beta-1b after a first attack suggestive of multiple ... -DG News

(PRN) - Alternative Energy Sources Appoints John J. Holland as EVP ...  Aug 17, 2006
...[+]. (PRN) - Trial Results Published in Neurology Show Risk of Developing Multiple Sclerosis Significantly Reduced with Interferon Beta-1b Early Treatment ... ... -Bolsamania.com

Betaseron(R) approved in Canada as treatment for the earliest ...  Aug 4, 2006
4 /CNW/ - (Berlex Canada Inc.) a wholly owned affiliate of Schering AG announced today that Betaseron(R) (interferon beta-1b), has been granted marketing ... -Canada NewsWire

Why are doctors so reluctant to prescribe treatment for MS?  Aug 3, 2006
The immuno modulators Avonex (interferon beta 1a), Betaferon (interferon beta 1b) and Copaxone (glatiramer) are drugs that reduce the frequency and severity of ... -Times Online

Betaferon Approved in Canada as Treatment for the Earliest Stages ...  Aug 3, 2006
BERLIN, August 3, 2006-Schering AG, Germany (FSE: SCH, NYSE: SHR) announced today that Betaferon® (interferon beta-1b, marketed as Betaseron® in Canada by ... -PharmaLive.com

New Autoinjection Device Designed to Work With Interferon beta-1b ...  Jul 12, 2006
...today announced the availability of Betaject® 3, a new autoinjection device specifically designed to work with Betaseron® (interferon beta-1b) as an optional ... -DG News

/CORRECTION -- Berlex, Inc./  Jul 11, 2006
...today announced the availability of Betaject(R) 3, a new autoinjection device specifically designed to work with Betaseron(R) (interferon beta-1b) as an ... -Genetic Engineering News

COPAXONE(R) Reduced Relapses By 75 Percent in Both Treatment-Naive ...  Jun 20, 2006
CITY, Mo., June 20 /PRNewswire/ -- Both relapsing-remitting multiple sclerosis (RRMS) patients switching from Betaseron(R) (interferon beta-1b) to COPAXONE(R ... -PR Newswire

COPAXONE Reduced Relapses By 75 Percent in Both Treatment-Naive ...  Jun 21, 2006
KANSAS CITY -- Both relapsing-remitting multiple sclerosis (RRMS) patients switching from Betaseron(R) (interferon beta-1b) to COPAXONE(R) (glatiramer acetate ... -dBusinessNews Kansas City

COPAXONE(R) Reduced Relapses By 75 Percent in Both Treatment-Naive ...  Jun 21, 2006
KANSAS CITY, MO, USA | Jun 20, 2006 | Both relapsing-remitting multiple sclerosis (RRMS) patients switching from Betaseron® (interferon beta-1b) to COPAXONE ... -PipelineReview.com

Celera Could Get $365M For Selling Cathepsin S Program  Jun 21, 2006
It plans to develop CRA-028129 initially for multiple sclerosis, adding to an existing Phase III program exploring high-dose interferon beta-1b and a Phase II ... -BioWorld Online

Celera Genomics Announces the Sale of Its Cathepsin S Inhibitor ...  Jun 21, 2006
This will add to our existing Phase III program exploring high dose interferon beta-1b and our Phase II program for alemtuzumab in MS.". ... -PharmaLive.com

Bayer takeover of Schering successful  Jun 21, 2006
...hormonal therapies business, including the blockbuster Yasmin oral contraceptive franchise, cancer drugs and Betaseron (interferon beta-1b) for multiple ... -Pharma Times (subscription)



Life-altering encounter with MS  May 1, 2006
Treatments, such as the administration beneath the skin of interferon beta-1b (Betaferon), can relieve symptoms or modify the course of the disease by ... - INQ7.net

Schering AG receives positive CHMP opinion for EU approval of ...  May 2, 2006
Products for Human Use (CHMP) recommending that the European Commission grants an extension of the indication for Betaferon® (interferon beta-1b) to add the ... - PharmaLive.com





New Survey of Neurologists Sheds Light on Trends for MS Therapy  Feb 16, 2006
General Information The Image of MS and the neurologist survey are sponsored by Berlex, Inc., marketers of Betaseron® (interferon beta-1b). ... - PharmaLive.com,

Clorox: Worst over for rising commodity costs  Feb 24, 2006
In another announcement, Chiron said Schering AG agreed to purchase its assets used to manufacture Betaseron interferon beta-1b products to treat multiple ... - San Jose Mercury News,

Schering to buy or lease all Chiron assets used to produce ...  Feb 27, 2006
...joint collaboration agreement to purchase or lease all assets used by Chiron in the manufacture for Schering of MS drug Betaseron interferon beta-1b products. ... - Forbes

Schering says 2005 was a 'record year  Feb 20, 2006
Schering's top-selling product, the multiple sclerosis drug Betaferon/Betaseron (interferon beta-1b) also climbed 12% in the quarter to 240 million euros, an ... - Pharma Times (subscription),

Berlex Files Application for Use of Betaseron in Patients with a ...  Feb 23, 2006
...of a supplemental biologics license application (sBLA) requesting an expanded label for its multiple sclerosis (MS) therapy, Betaseron® (interferon beta-1b). ... - Yahoo! News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional